Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1012

Sort by

Sort Order Select

Journal Articles

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Akinori Yoda, PhD, Daisuke Morishita, PhD, Akio Mizutani, PhD, Yoshihiko Satoh, PhD, Yotaro Ochi, MD, Yasuhito Nannya, MD PhD, Hideki Makishima, MD PhD, Hiroshi Miyake, PhD, Seishi Ogawa, MD PhD

Blood (2019) 134 (Supplement_1): 404.

https://doi.org/10.1182/blood-2019-131559

Published: 2019

Journal Articles

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Rana Gbyli, MS, Yuanbin Song, MD, Wei Liu, PhD, Yimeng Gao, PhD, Namrata S Chandhok, MD, Xiaoying Fu, MD, Xiaman Wang, MD PhD, Amisha Patel, MS, Ranjini Sundaram, PhD, Toma Tebaldi, PhD, Giulia Biancon, PhD, Anastasia Ardasheva, BS, Ashley Qin, Mukhtar Sadykov, MD, Padmavathi Mamillapalli, BS, Richard Flavell, PhD, Thomas Prebet, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD

Blood (2019) 134 (Supplement_1): 4222.

https://doi.org/10.1182/blood-2019-130814

Published: 2019

Journal Articles

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Xiaoyu Lin, Tamar Uziel, PhD, Xin Lu, Lu Zhang, Xiaoli Huang, Qi Zhang, PhD, Antonio Cavazos, Lina Han, PhD, Yu Shen, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1369.

https://doi.org/10.1182/blood-2019-128618

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

B. Hilda Ye, PhD, Elaine Chung, PhD, Kith Pradhan, PhD, Ana Acuna-Villaorduna, MD, Yanhua Wang, MD PhD, Aditi Shastri, MD, Advaitha Madireddy, PhD, Amit Verma, MBBS, R.Alejandro Sica, MD, Murali Janakiram, MD MS

Blood (2019) 134 (Supplement_1): 3779.

https://doi.org/10.1182/blood-2019-131364

Published: 2019

Journal Articles

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

Wittawat Chantkran, MD MSc, Daniella Zheleva, PhD, Sheelagh Frame, PhD, Ya-Ching Hsieh, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath

Blood (2019) 134 (Supplement_1): 3938.

https://doi.org/10.1182/blood-2019-124072

Published: 2019

Journal Articles

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Namrata S Chandhok, MD, Wei Wei, MD PhD, Ranjit Bindra, MD PhD, Stephanie Halene, MD, Yu Shyr, Jing Li, PhD, Michael Berens, PhD, Chris Karlovich, PhD, S. Percy Ivy, MD, Thomas Prebet, MD PhD

Blood (2019) 134 (Supplement_1): 3909.

https://doi.org/10.1182/blood-2019-129168

Published: 2019

Journal Articles

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

Laura Monaghan, BSc, Matthew Edward Massett, MSc, BSc, Roderick P Bunschoten, BSc, Petrisor Alin Pirvan, MSc, BSc, Alex Hoose, Bsc, PhD, Taeju Park, BSc, Joana Bittencourt-Silvestre, BSc, MSc, Robert M J Liskamp, BSc, PhD, Heather G Jørgensen, Xu Huang, BSc, PhD

Blood (2019) 134 (Supplement_1): 3756.

https://doi.org/10.1182/blood-2019-125355

Published: 2019

Journal Articles

DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors

Aksinija A Kogan, BS, MS, Lena J Mclaughlin, BS, Maria R. Baer, MD, Stephen Baylin, MD, Michael Topper, BS, Feyruz V. Rassool, BSc, PhD

Blood (2019) 134 (Supplement_1): 3763.

https://doi.org/10.1182/blood-2019-129535

Published: 2019

Journal Articles

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models

Heekyung Chung, PhD, Emily Creger, Lauren Sitts, Kevin Chiu, Chi-Ching Mak, PhD, Sunil KC, PhD, Betty Tam, PhD, Gail Bucci, Josh Stewart, Timothy Phalen, PhD, Steven Cha, MD

Blood (2019) 134 (Supplement_1): 3913.

https://doi.org/10.1182/blood-2019-131209

Published: 2019

Journal Articles

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

Blood (2019) 134 (Supplement_1): 4142.

https://doi.org/10.1182/blood-2019-126500

Published: 2019

Journal Articles

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models

Heekyung Chung, PhD, Emily Creger, Lauren Sitts, Kevin Chiu, Chi-Ching Mak, PhD, Sunil KC, PhD, Betty Tam, PhD, Gail Bucci, Josh Stewart, Timothy Phalen, PhD, Steven Cha, MD

Blood (2019) 134 (Supplement_1): 4059.

https://doi.org/10.1182/blood-2019-124812

Published: 2019

Journal Articles

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Chunfen Zhang, MD, Ritul Sharma, MSc., Thakur Satbir, PhD, Allison Cheney, Olena Vaske, PhD, Lauren Sanders, Jessica Boklan, MD, Victor A. Lewis, MD, Ronald Anderson, MDFRCPC, Olga Kovalchuk, MD, PhD, Norman J. Lacayo, MD, Aru Narendran, MD PhD, Kevin J. Bielamowicz, MD

Blood (2019) 134 (Supplement_1): 2633.

https://doi.org/10.1182/blood-2019-131444

Published: 2019

Journal Articles

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

Mohammad Hojjat-Farsangi, MSc,PhD, Amineh Ghaderi, MSc, AmirHossein Daneshmanesh, MD PhD, Jemina Lehto, MSc, Ali Moshfegh, MSc,PhD, Parviz Kokhaei, MSc,PhD, Jan Vågberg, MSc,PhD, Elisabeth Olsson, MSc,PhD, Charlotta Löfberg, MSc,PhD, Charlotta Carina Norström, MSc,PhD, Johan Schultz, MSc,PhD, Martin Norin, MSc,PhD, Thomas Olin, MSc,PhD, Elias Drakos, MD PhD Prof., George Z. Rassidakis, MD PhD Prof., Anders Österborg, MD PhD, Håkan Mellstedt, MD PhD Prof.

Blood (2019) 134 (Supplement_1): 2565.

https://doi.org/10.1182/blood-2019-126801

Published: 2019

Journal Articles

BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML

Joseph M Brandwein, MD, Asmaa Basonbul, MSc

Blood (2019) 134 (Supplement_1): 2646.

https://doi.org/10.1182/blood-2019-129529

Published: 2019

Journal Articles

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

Anthony Quagliano, BS, Anilkumar Gopalakrishnapillai, PhD, E. Anders Kolb, MD, Sonali Barwe, PhD MSc

Blood (2019) 134 (Supplement_1): 2628.

https://doi.org/10.1182/blood-2019-129198

Published: 2019

Journal Articles

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

Anne W. J. Martens, MSc, Susanne R. Janssen, MSc, Ingrid A.M. Derks, Sanne Tonino, MD PhD, Eric Eldering, Gerritje J. W. van der Windt, Arnon P. Kater, MD PhD

Blood (2019) 134 (Supplement_1): 3043.

https://doi.org/10.1182/blood-2019-123350

Published: 2019

Journal Articles

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ekaterina Kim, MS, Hongying Zhang, MD PhD, Mariela Sivina, Alicia Vaca, PhD, Philip A. Thompson, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 3051.

https://doi.org/10.1182/blood-2019-124473

Published: 2019

Journal Articles

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Inge Oudaert, MSc, Sylvia Faict, MSc, Ludovic D'Auria, PhD, Jonas Dehairs, PhD, Ken Maes, Philip Vlummens, MD, Lotte Jacobs, BSc, Kim De Veirman, Elke De Bruyne, PhD, Karel Fostier, MD, Isabelle Vande Broek, MD PhD, Rik Schots, Karin Vanderkerken, PhD, Johannes V. Swinnen, PhD, Eline Menu, PhD

Blood (2019) 134 (Supplement_1): 3058.

https://doi.org/10.1182/blood-2019-122857

Published: 2019

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

https://doi.org/10.1182/blood-2019-126827

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

S-Phase Progression of North American ATLL Cells Is Critically Regulated By the Proto-Oncogene BCL6 and Targetable By PARP Inhibition

Combination of CYC065, a Second Generation CDK2/9 Inhibitor, with Venetoclax or Standard Chemotherapies - a Novel Therapeutic Approach for Acute Myeloid Leukaemia (AML)

The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome

Efficient Elimination of Acute Myeloid Leukemia Cells through Inhibition of KDM4A in Combination with PARP Inhibition

DNA Methyltransferase Inhibitors Promote Homologous Recombination Deficiency through Induction of Immune Signaling, Sensitizing Acute Myeloid Leukemia Cells to PARP Inhibitors

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Tumor Protein p53 (TP53)-Mutant Acute Myeloid Leukemia Models

Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way

SM09419, a Novel, Small-Molecule CDC-like Kinase (CLK) Inhibitor, Demonstrates Strong Inhibition of the Wnt Signaling Pathway and Antitumor Effects in Mantle Cell Lymphoma Models

Establishing a Novel in Vitro Informed Precision Clinical Trial Pathway for Refractory Pediatric Leukemia

Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells

BCL-2 Inhibitor Venetoclax Enhances Temozolomide Sensitivity in AML

Modulation of CD81 By Epigenetic Drug Combination Sensitizes Acute Lymphoblastic Leukemia Via Decreased BTK Signaling

CD3xCD19 Dart Treatment Is Efficient in Venetoclax Resistant CLL and Reverses T Cell Dysfunction

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

The Exosomal Transfer of Acid Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only